0.23
price up icon3.00%   0.0067
after-market Handel nachbörslich: .23
loading
Schlusskurs vom Vortag:
$0.2233
Offen:
$0.2233
24-Stunden-Volumen:
174.05K
Relative Volume:
0.07
Marktkapitalisierung:
$2.33M
Einnahmen:
$2.88M
Nettoeinkommen (Verlust:
$-5.12M
KGV:
-0.000852
EPS:
-269.9888
Netto-Cashflow:
-
1W Leistung:
+1.77%
1M Leistung:
+2.50%
6M Leistung:
-81.75%
1J Leistung:
-96.35%
1-Tages-Spanne:
Value
$0.2204
$0.23
1-Wochen-Bereich:
Value
$0.2106
$0.2554
52-Wochen-Spanne:
Value
$0.2055
$14.22

Scisparc Ltd Stock (SPRC) Company Profile

Name
Firmenname
Scisparc Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
3
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
SPRC's Discussions on Twitter

Scisparc Ltd Aktie (SPRC) Neueste Nachrichten

pulisher
Nov 04, 2024

SciSparc Ltd. Reports Changes in Financial Position - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Oct 23, 2024

SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks

Oct 23, 2024
pulisher
Oct 22, 2024

SciSparc Ltd. Reschedules Annual General Meeting - TipRanks

Oct 22, 2024
pulisher
Oct 16, 2024

Examining SPRC’s book value per share for the latest quarter - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex

Oct 16, 2024
pulisher
Oct 09, 2024

SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com

Oct 09, 2024
pulisher
Oct 08, 2024

SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel

Oct 01, 2024
pulisher
Oct 01, 2024

SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena

Oct 01, 2024
pulisher
Oct 01, 2024

SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN

Oct 01, 2024
pulisher
Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks

Sep 30, 2024
pulisher
Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News

Sep 30, 2024
pulisher
Sep 29, 2024

SciSparc signs LOI to sell entire ownership in MitoCareX - MSN

Sep 29, 2024
pulisher
Sep 27, 2024

SciSparc Ltd. Proposes Reverse Stock Split - TipRanks

Sep 27, 2024
pulisher
Sep 26, 2024

SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire

Sep 26, 2024
pulisher
Sep 25, 2024

Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Smartgroup Announces Major Shareholding Changes - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Science Group PLC Executes Share Buyback - TipRanks

Sep 25, 2024
pulisher
Sep 24, 2024

Site Group Plans Massive New Share Issue - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle

Sep 24, 2024
pulisher
Sep 24, 2024

SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts

Sep 24, 2024
pulisher
Sep 24, 2024

Clearmind, SciSparc slide amid weight-loss study results - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter

Sep 24, 2024
pulisher
Sep 24, 2024

UBS Cuts Stake in Spirent Communications - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree maintains expectations amid tough market conditions. - Research the market

Sep 24, 2024
pulisher
Sep 24, 2024

UK recruiter SThree falls on lower Q3 net fee - XM

Sep 24, 2024
pulisher
Sep 24, 2024

SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK

Sep 24, 2024
pulisher
Sep 24, 2024

Science Group PLC Announces Share Buyback - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree plc Navigates Market Headwinds in Q3 - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree Net Fees Fall Amid Challenging Environment - MarketWatch

Sep 24, 2024
pulisher
Sep 24, 2024

Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.

Sep 24, 2024
pulisher
Sep 23, 2024

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World

Sep 23, 2024

Finanzdaten der Scisparc Ltd-Aktie (SPRC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):